AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3729461 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC (angiotensin-induced hypertension chemotherapy)
Number of subjects: 40
Study 3729461 — intervention group
Group type: COMPARATOR
Intervention: Non-IHC (control)
Number of subjects: 40
Study 3729461 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC
Number of subjects: 40
Study 3729461 — intervention group
Group type: COMPARATOR
Intervention: Non-IHC
Number of subjects: 40
Study 3729461 — intervention group
Group type: EXPERIMENTAL
Intervention: Open trial (IHC)
Number of subjects: 40
Study 29743284 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 180
Study 29743284 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 180
Study 29743284 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Vertebroplasty and Sham)
Number of subjects: 180
Study 26961287 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous hydroxyapatite/collagen composite (HAp/Col)
Number of subjects: 126
Study 26961287 — intervention group
Group type: COMPARATOR
Intervention: Porous β‐tricalcium phosphate (β‐TCP)
Number of subjects: 126
Study 25028994 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 33
Study 25028994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 33
Study 25028994 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study 22037965 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-skills intervention (Side by Side)
Number of subjects: 72
Study 22037965 — intervention group
Group type: COMPARATOR
Intervention: Couples Control Program (cancer education)
Number of subjects: 72
Study 20569841 — intervention group
Group type: EXPERIMENTAL
Intervention: Janani Suraksha Yojana (JSY) payments
Number of subjects: 0
Study 17906015 — intervention group
Group type: EXPERIMENTAL
Intervention: Advised-coitus group
Number of subjects: 210
Study 17906015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 16336070 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone + Mail Counseling condition
Number of subjects: 72
Study 16336070 — intervention group
Group type: COMPARATOR
Intervention: Mail Support condition
Number of subjects: 72
Study 12084138 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 187
Study 12084138 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 187
Study 7797925 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent cold-adapted recombinant (CR) influenza virus vaccine
Number of subjects: 0
Study 7797925 — intervention group
Group type: COMPARATOR
Intervention: Monovalent A/H1N1, A/H3N2, or B vaccine
Number of subjects: 0
Study 7797925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2159706 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly intermittent regimen of AZT and 2',3'-dideoxycytidine
Number of subjects: 0
Study 2159706 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly alternating regimen of AZT and 2',3'-dideoxycytidine
Number of subjects: 0
Study 2159706 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly alternating regimen of AZT and 2',3'-dideoxycytidine
Number of subjects: 0
Study 2159706 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (AZT)
Number of subjects: 0
Study 2159706 — intervention group
Group type: COMPARATOR
Intervention: 2',3'-dideoxycytidine
Number of subjects: 0
Study 6986104 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 38
Study 6986104 — intervention group
Group type: COMPARATOR
Intervention: Late extubation
Number of subjects: 38
Study 31597624 — intervention group
Group type: EXPERIMENTAL
Intervention: Early controlled motion (ECM) of the ankle, performed five times a day from week 3 to week 8 after rupture.
Number of subjects: 130
Study 31597624 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation for 8 weeks.
Number of subjects: 130
Study 31597624 — intervention group
Group type: EXPERIMENTAL
Intervention: Early controlled motion (ECM) of the ankle.
Number of subjects: 130
Study 30277627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ulinastatin (UTI) administration
Number of subjects: 86
Study 30277627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 27690682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (6 puffs, 2.4 mg sublingual) and glucagon (1 mg intravenously)
Number of subjects: 455
Study 27690682 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (6 puffs) and hyoscine-n-butyl bromide (20 mg intravenously)
Number of subjects: 455
Study 25427566 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP‐containing cream (GC Tooth Mouse, non‐fluoride) after fluoride toothpaste (1,400 ppm NaF)
Number of subjects: 13
Study 25427566 — intervention group
Group type: COMPARATOR
Intervention: Prolonged application of fluoride toothpaste (1,400 ppm NaF; positive control)
Number of subjects: 13
Study 25427566 — intervention group
Group type: COMPARATOR
Intervention: Prolonged application of fluoride-free toothpaste (negative control)
Number of subjects: 13
Study 23617551 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 μg
Number of subjects: 18
Study 23617551 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 18
Study 23617551 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 μg + Formoterol 12 μg
Number of subjects: 18
Study 23617551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22084331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing assessment every 12 weeks (n = 124)
Number of subjects: 250
Study 22084331 — intervention group
Group type: COMPARATOR
Intervention: Dosing assessment every 4 weeks (n = 126)
Number of subjects: 250
Study 19408012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy with adjuvant TACE (HT arm)
Number of subjects: 115
Study 19408012 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone (HA arm)
Number of subjects: 115
Study 17218576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg; maximum, 10 mg)
Number of subjects: 69
Study 17218576 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 69
Study 16398842 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (n = 5)
Number of subjects: 12
Study 16398842 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (control group)
Number of subjects: 12
Study 16398842 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation combined with bisphosphonate treatment (non-trial patients, n = 11)
Number of subjects: 12
Study 12875343 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally implanted gentamicin (miniseptopal or sponge)
Number of subjects: 20
Study 10582505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber surgical gloves (thicknesses: 0.24, 0.61, and 1.02 mm)
Number of subjects: 10
Study 10582505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton glove
Number of subjects: 10
Study 10582505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber glove
Number of subjects: 10
Study 10582505 — intervention group
Group type: COMPARATOR
Intervention: Barehanded
Number of subjects: 10
Study 8542565 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education and written notification of excessive prescribing
Number of subjects: 54
Study 8542565 — intervention group
Group type: EXPERIMENTAL
Intervention: Written notification of excessive prescribing only
Number of subjects: 54
Study 8542565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 1878641 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 15
Study 1878641 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 15
Study 1878641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7143158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 49
Study 7143158 — intervention group
Group type: COMPARATOR
Intervention: Nonhypnotic techniques
Number of subjects: 49
Study 31511398 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 loss-of-function variants (LOFV)
Number of subjects: 10
Study 28115488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 228
Study 28115488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 228
Study 25425257 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion Replacement Training (LRT)
Number of subjects: 10
Study 25425257 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing (STA)
Number of subjects: 10
Study 25425257 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 25425257 — intervention group
Group type: COMPARATOR
Intervention: All conditions (CON, STA, LRT)
Number of subjects: 10
Study 24829493 — intervention group
Group type: EXPERIMENTAL
Intervention: CanolaDHA (high-oleic acid canola oil with docosahexaenoic acid)
Number of subjects: 130
Study 24829493 — intervention group
Group type: COMPARATOR
Intervention: Canola (conventional canola oil)
Number of subjects: 130
Study 24829493 — intervention group
Group type: COMPARATOR
Intervention: CornSaff (blend of corn and safflower oil)
Number of subjects: 130
Study 24829493 — intervention group
Group type: COMPARATOR
Intervention: FlaxSaff (blend of flax and safflower oils)
Number of subjects: 130
Study 24829493 — intervention group
Group type: COMPARATOR
Intervention: CanolaOleic (high-oleic acid canola oil)
Number of subjects: 130
Study 23033885 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diary (e-diary) with integrated peak flow meter
Number of subjects: 47
Study 23033885 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 47
Study 19744315 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physiotherapy sessions
Number of subjects: 22
Study 19744315 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations from women attending group sessions
Number of subjects: 22
Study 17123710 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmeatal cochlear laser (TCL) stimulation
Number of subjects: 0
Study 17123710 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 14989693 — intervention group
Group type: EXPERIMENTAL
Intervention: SMCP alone
Number of subjects: 42
Study 14989693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hynes alone
Number of subjects: 42
Study 14989693 — intervention group
Group type: EXPERIMENTAL
Intervention: SMCP+Hynes
Number of subjects: 42
Study 14989693 — intervention group
Group type: EXPERIMENTAL
Intervention: SMCP repair
Number of subjects: 42
Study 12472324 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (40,000 units administered weekly by subcutaneous injection)
Number of subjects: 1302
Study 12472324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1302
Study 12472324 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 1302
Study 9795455 — intervention group
Group type: COMPARATOR
Intervention: alpha E beta 7 integrin expression on T cells of lamina propria (LPL)
Number of subjects: 38
Study 9795455 — intervention group
Group type: COMPARATOR
Intervention: alpha E beta 7 integrin expression on intra-epithelial lymphocytes (IEL)
Number of subjects: 38
Study 9795455 — intervention group
Group type: COMPARATOR
Intervention: CD4/CD8 ratio in LPL
Number of subjects: 38
Study 9795455 — intervention group
Group type: COMPARATOR
Intervention: Regional differences in CD4/CD8 ratio
Number of subjects: 38
Study 9795455 — intervention group
Group type: COMPARATOR
Intervention: alpha E beta 7 integrin expression in LPL
Number of subjects: 38
Study 7635134 — intervention group
Group type: EXPERIMENTAL
Intervention: German version of Broadbent's Cognitive Failures Questionnaire
Number of subjects: 0
Study 7635134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventories of trait anxiety, coping styles, and action control
Number of subjects: 0
Study 7635134 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood factor analysis of the questionnaire
Number of subjects: 0
Study 7635134 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidimensionality of the construct
Number of subjects: 0
Study 2236459 — intervention group
Group type: EXPERIMENTAL
Intervention: Enciprazine (5 mg t.i.d., 10 mg t.i.d., and 20 mg t.i.d.)
Number of subjects: 0
Study 2236459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2236459 — intervention group
Group type: EXPERIMENTAL
Intervention: Enciprazine
Number of subjects: 0
Study 389282 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate 0.1%
Number of subjects: 0
Study 389282 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.1%
Number of subjects: 0
Study 389282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30535378 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and cognitive ability
Number of subjects: 0
Study 27837660 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation + active CBM-I
Number of subjects: 0
Study 27837660 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation + control CBM-I
Number of subjects: 0
Study 25078875 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Su Corazón, Su Vida curriculum, consisting of 8 educational sessions.
Number of subjects: 90
Study 23972025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (MA.12 trial)
Number of subjects: 101
Study 23972025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MA.12 trial)
Number of subjects: 101
Study 23972025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (BC cohort)
Number of subjects: 101
Study 23972025 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (BC cohort)
Number of subjects: 101
Study 21164503 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day high-fat high-calorie (HFHC) dietary intervention
Number of subjects: 46
Study 19757196 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (Nadroparin)
Number of subjects: 0
Study 19757196 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16889458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT) for 12 weeks
Number of subjects: 56
Study 16889458 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 100 mg/day for 12 weeks
Number of subjects: 56
Study 15171752 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone followed by rosiglitazone (4 mg/day) or pioglitazone (30 mg/day)
Number of subjects: 172
Study 15171752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antidiabetic medication)
Number of subjects: 172
Study 15171752 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone followed by rosiglitazone or pioglitazone
Number of subjects: 172
Study 11566518 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (oxybuprocaine 0.4%)
Number of subjects: 291
Study 11566518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anesthesia (topical anesthesia and propofol sedation)
Number of subjects: 291
Study 11566518 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar/peribulbar anesthesia (prilocaine 1.5%)
Number of subjects: 291
Study 9054252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (50 ng.kg-1.min-1 for 30 min before induction, then 7 ng.kg-1.min-1 until end of surgery)
Number of subjects: 80
Study 9054252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 80
Study 9054252 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study 8201140 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (BAC 0.10%)
Number of subjects: 27
Study 8201140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3608513 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous human fibronectin (300 micrograms/ml), mixed with gentamicin and artificial tears, 4 times a day
Number of subjects: 6
Study 3608513 — intervention group
Group type: COMPARATOR
Intervention: Control (gentamicin and artificial tears)
Number of subjects: 6
Study 29370352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue liquefaction liposuction (TLL)
Number of subjects: 31
Study 29370352 — intervention group
Group type: COMPARATOR
Intervention: Suction-assisted liposuction (SAL)
Number of subjects: 31
Study 27309589 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led debriefing (high-level facilitation)
Number of subjects: 37
Study 27309589 — intervention group
Group type: COMPARATOR
Intervention: Within-team debriefing (low-level facilitation)
Number of subjects: 37
Study 25658097 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 157
Study 25658097 — intervention group
Group type: COMPARATOR
Intervention: ABC/3TC+EFV
Number of subjects: 157
Study 24021497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (20-50 mg/d)
Number of subjects: 129
Study 24021497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 24021497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Number of subjects: 129
Study 21917907 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin administration (twice daily injections)
Number of subjects: 0
Study 21917907 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration (twice daily injections)
Number of subjects: 0
Study 21917907 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance
Number of subjects: 0
Study 21917907 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin administration
Number of subjects: 0
Study 17557312 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (respiratory stimulant), dosage and duration not specified
Number of subjects: 0
Study 17007369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg once daily for 3 weeks)
Number of subjects: 60
Study 17007369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once daily for 3 weeks)
Number of subjects: 60
Study 17007369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12781882 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation and surgery
Number of subjects: 1116
Study 12781882 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation and surgery (concurrent)
Number of subjects: 1116
Study 12781882 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation and surgery (sequential)
Number of subjects: 1116
Study 12413260 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique P (IVECG signal from NaHCO3 flushed catheter)
Number of subjects: 100
Study 12413260 — intervention group
Group type: COMPARATOR
Intervention: Technique G (IVECG signal from guide wire)
Number of subjects: 100
Study 12413260 — intervention group
Group type: COMPARATOR
Intervention: Technique G
Number of subjects: 100
Study 12413260 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique P
Number of subjects: 100
Study 9669144 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study 9669144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 9669144 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with calcium and vitamin D
Number of subjects: 0
Study 7928312 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 845
Study 2691780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride
Number of subjects: 16
Study 2691780 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 16
Study 2691780 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 16
Study 4835842 — intervention group
Group type: EXPERIMENTAL
Intervention: (87m)Sr scintigraphy
Number of subjects: 201
Study 4835842 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc polyphosphate scintigraphy
Number of subjects: 201
Study 4835842 — intervention group
Group type: COMPARATOR
Intervention: x-ray
Number of subjects: 201
Study 4835842 — intervention group
Group type: COMPARATOR
Intervention: x-ray and (87m)Sr surveys
Number of subjects: 201
Study 31831363 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (2400 mg/d) for 8 weeks
Number of subjects: 50
Study 31831363 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 50
Study 31593702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg weekly subcutaneous injections)
Number of subjects: 47
Study 31593702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31593702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 47
Study 28165552 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCKD1
Number of subjects: 0
Study 28165552 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCKD2
Number of subjects: 0
Study 28165552 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCKD3
Number of subjects: 0
Study 28165552 — intervention group
Group type: COMPARATOR
Intervention: VLCKD
Number of subjects: 0
Study 28165552 — intervention group
Group type: COMPARATOR
Intervention: Control Groups (CG1 and CG2)
Number of subjects: 0
Study 26030518 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib and fulvestrant
Number of subjects: 521
Study 26030518 — intervention group
Group type: COMPARATOR
Intervention: placebo and fulvestrant
Number of subjects: 521
Study 23488834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild propofol sedation
Number of subjects: 30
Study 23488834 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep propofol sedation
Number of subjects: 30
Study 20976617 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week Theory of Mind (ToM) treatment
Number of subjects: 40
Study 20976617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40